title: Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.
abstract: BACKGROUND
  Chronic urticaria is known to debilitate a person's quality of life via sleep disruption, itching lesions, fatigue, social isolation, energy loss and emotional/sexual difficulties. Once-daily desloratadine significantly improved the signs and symptoms of CIU.
  
  
  OBJECTIVE
  Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU). Study population One-hundred twenty-one consecutive patients with CIU present for at least 6 weeks prior to inclusion and with a current flare of at least 3 weeks, were included in the study in 24 Belgian centres.
  
  
  RESULTS
  The mean dermatology life quality index (DLQI) significantly decreased from baseline to day 7 and further to day 42. Sixty per cent and 77% of patients had a clinically significant change (i.e. a decrease of at least 2 points) at day 7 or day 42, respectively, as compared with that of day 0. Change in pruritus and size of the hives significantly correlated with the change in the score of the quality of life. One-third of patients experienced complete relief whereas in 1 of 10 patients no effect was experienced.
  
  
  CONCLUSIONS
  Desloratadine significantly improves the quality of life of patients with chronic idiopathic urticaria as reflected by the dermatology life quality index (DLQI).
authors.affiliation: Department of Dermatology, Université Catholique de Louvain, Brussels, Belgium. Jean-marie.Lachappelle@derm.ucl.ac.be
authors.forename: J M
authors.initials: JM
authors.lastname: Lachapelle
authors.forename: J
authors.initials: J
authors.lastname: Decroix
authors.forename: A
authors.initials: A
authors.lastname: Henrijean
authors.forename: P P
authors.initials: PP
authors.lastname: Roquet-Gravy
authors.forename: A
authors.initials: A
authors.lastname: De Swerdt
authors.forename: H
authors.initials: H
authors.lastname: Boonen
authors.forename: M
authors.initials: M
authors.lastname: Lecuyer
authors.forename: E
authors.initials: E
authors.lastname: Suys
authors.forename: G
authors.initials: G
authors.lastname: Speelman
authors.forename: N
authors.initials: N
authors.lastname: Vastesaeger
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001530:Belgium; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine; C121345:desloratadine